Flunazine Equine Paste
This treatment applies to the following species:(flunixin meglumine)
ANADA 200-581, Approved by FDA
SYRINGE CONTAINS FLUNIXIN MEGLUMINE EQUIVALENT TO 1500 mg FLUNIXIN
FOR ORAL USE IN HORSES ONLY
KEEP OUT OF REACH OF CHILDREN
Warning
Do not use in horses intended for human consumption.Flunazine Equine Paste Caution
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Flunazine Equine Paste Indications
For the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.
ACTIVITY: Flunixin meglumine is a potent, nonnarcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. It is significantly more potent than pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test. Oral studies in the horse show onset of flunixin activity occurs within 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of activity is 24 to 36 hours.
Contraindications
There are no known contraindications to this drug when used as directed.
Precautions
The effect of flunixin meglumine on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of flunixin meglumine.Side Effects
During field studies with flunixin meglumine, no significant side effects were reported.Dosage and Administration
The recommended dose of flunixin meglumine is 0.5 mg per lb of body weight once daily. The Flunazine® Equine Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs (see dosage table). One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.DOSAGE TABLE
Syringe Mark* |
Horse Weight (lbs) |
Flunazine® Equine Paste Delivered (g) |
mg Flunixin Delivered |
0 |
--- |
--- |
--- |
250 |
250 |
2.5 |
125 |
500 |
500 |
5.0 |
250 |
750 |
750 |
7.5 |
375 |
1000 |
1000 |
10.0 |
500 |
* Use dial edge nearest syringe barrel to mark dose.
The paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.
Treatment may be given initially by intravenous or intramuscular injection of Flunazine Injectable Solution, followed by Flunazine® Equine Paste on Days 2 to 5. Flunixin meglumine treatment should not exceed 5 consecutive days.
TOXICITY: No toxic effects were observed in rats given oral flunixin meglumine 2 mg/kg per day for 42 days. Higher doses produced ulceration of the gastrointestinal tract. The emetic dose in dogs is between 150 and 250 mg/kg. Flunixin was well tolerated in monkeys dosed daily with 4 mg/kg for 56 days. No adverse effects occurred in horses dosed orally with 1.0 or 1.5 mg/lb for 5 consecutive days.
Storage
Store at 20°C - 25°C (69°F - 77°F); excursions permitted between 15°C - 30°C (between 59°F - 86°F).Apple Flavored
Flunazine® is a Registered Trademark of Bimeda, Inc.
N.A. Corp. Address: Bimeda, Inc., One Tower Lane, Oakbrook Terrace, IL 60181
Manufactured by: Bimeda-MTC Animal Health Inc., Cambridge, ON Canada N3C 2W4
Manufactured for: Bimeda, Inc., Le Sueur, MN 56058
www.bimedaus.com
Net Wt. 30g |
1FLU015 |
8FLU021A Rev. 01/15 |
Contains: 12 - Flunazine® (flunixin meglumine) Equine Paste Syringes 30 g each |
1FLU015 |
8FLU030 Rev. 10/14 |
CPN: 1399114.1
Div. Cross Vetpharm Group, Ltd.
475 NORTH MARTINGALE ROAD, SUITE 1200, SCHAUMBURG, IL, 60173
Telephone: | 630-928-0361 | |
Fax: | 630-928-0362 | |
Website: | www.bimedaus.com | |
Email: | us-sales@bimeda.com |
THIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details. |
Copyright © 2024 Animalytix LLC. Updated: 2024-08-26